evipedia.ai ← Back to Review

Audit: QRS - Thioctic Acid for Hair Regrowth

Audit conducted on 08/07/2026 22:12 using AI4L / Opus 4.8

Iterations

Summary

Items Count
Total 91
Passed 84
Failed 0
N/A 7
Pass Rate 100.00%
  • Total = Passed + Failed + N/A
  • Pass Rate = Passed / (Passed + Failed) × 100
  • N/A items are excluded from the pass rate calculation

1. General Rules

# Description Result Comments
1.1 Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER. 🟢 All protocol doses, times, benefits, risks, contraindications, interactions, and monitoring values trace to the ER.
1.2 Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing. 🟢 At-a-Glance preserves “plausible but largely unproven”; speculative framing retained.
1.3 The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”). 🟢 Contraindications and risks carried at the same strength as the ER.
1.4 The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc. 🟢 Stop/caution items drawn from the ER Key Interactions & Contraindications section; no cross-category relabeling.
1.5 PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact. 🟢 The QRS carries no citations, PMIDs, NCTs, expert names, or brand names.
1.6 The QRS does not introduce new attributions. 🟢 No attributions present.

2. Focus, Tone & Audience

# Description Result Comments
2.1 The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing. 🟢 Sober, cautious, mechanism-aware tone mirrors the ER.
2.2 The tone of the QRS is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging 🟢 Balanced expert/accessible register maintained.
2.3 The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor 🟢 Presents evidence, not prescriptions.
2.4 The QRS avoids language that implies medical or clinical advice 🟢 No directive/advisory phrasing.
2.5 The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising” 🟢 Content is descriptive throughout.
2.6 The QRS never addresses “the reader” directly — it presents evidence, not guidance 🟢 No second-person address.
2.7 The QRS is written in plain language, avoiding unnecessary medical jargon 🟢 Terms are accessible; technicalities kept minimal.
2.8 Information is presented in a concise and very compact manner 🟢 Cells and list items are compact.
2.9 It DOES NOT address the reader directly 🟢 No “you”/”your” usage.
2.10 The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review. 🟢 Framing suits a proactive, risk-aware reader.
2.11 The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort. 🟢 Protocol/monitoring detail assumes an engaged reader.
2.12 The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort. 🟢 Not general-population framing.
2.13 Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience. 🟢 Weighting reflects the target audience.
2.14 The document’s own voice frames usage in longevity terms, not “anti-aging”. Proper names that contain “anti-aging” are quoted verbatim. 🟢 No “anti-aging” language present.
2.15 The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language. Direct quotes from sources are exempt. 🟢 Uses “gastrointestinal discomfort”, “blood sugar lowering” (as in the ER); no consumer slang.

3. Template Integrity

# Description Result Comments
3.1 The following labels and headings on the QRS are fixed and not modified: card/section headings, gate headings, tier labels, and Monitoring table column headers. 🟢 “Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment”, “Contraindications”, “Key Interactions”, tiers, and Marker/Target/Why are all intact.
3.2 All “…” from the [qrs_template] are present in the the QRS. 🟢 Full complement of named spans present.
3.3 Spans that are not addressed in a checklist item are left unchanged 🟢 No unrelated spans altered.

4. Formatting

# Description Result Comments
4.1 When the source ER section is empty, the QRS uses the ER’s own empty-state phrasing verbatim. Typical phrasings are “None documented in human trials to date” and “Not formally studied” N/A No mapped ER section is empty in a way requiring empty-state phrasing; absent tiers use display:none per 12.5/13.5.
4.2 Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label. 🟢 Protocol labels (“Typical Oral Dose”, “Best Time of Day”, “R-Isomer Dosing”) match the ER bullet labels.
4.3 Labels are not paraphrased, abbreviated, or invented. 🟢 Labels preserve the ER wording.
4.4 The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels. 🟢 No emoji indicators in the rendered content.
4.5 The QRS is designed to render on one A4 page. Any section that has more content in the ER than fits the per-section budget is condensed by the LLM, not extended onto a second page. 🟢 Content condensed to a single-page budget.

5. Metadata

# Description Result Comments
5.1 The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content. 🟢 Comment at lines 2–14, immediately after the doctype.
5.2 Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML. 🟢 Opening “—” line 3, closing “—” line 13.
5.3 The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet. 🟢 Enclosed in an HTML comment.
5.4 All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless required by YAML. 🟢 Only “duration” is quoted (contains a colon).
5.5 The filename of the source ER is stated as “er_filename: [er_filename]” 🟢 er_filename: thioctic_acid_hair_2026-0708-2001_Opus_ER.md
5.6 Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]” 🟢 qrs_prompt_version: 26.7.02
5.7 Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” 🟢 qrs_creation_date: 2026-0708-2204
5.8 The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]” 🟢 qrs_creator_ai_nickname: Opus
5.9 The nickname of the AI is just a single word model name without version, etc. 🟢 “Opus” is a single word.
5.10 The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]” 🟢 qrs_creator_ai_fullname: Opus 4.8
5.11 The full name of the AI consists of the [qrs_creator_ai_nickname] and the model version number and no additional qualifier 🟢 “Opus 4.8” — nickname plus version only.
5.12 The filename of the document is stated as “qrs_filename: [filename of this document]” 🟢 qrs_filename: thioctic_acid_hair_2026-0708-2001_Opus_QRS.html
5.13 All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless required by YAML. 🟢 Values clean and consistent.

6. Page Title & Header

# Description Result Comments
6.1 [page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet”. The [canonical_topic] is HTML-entity-encoded as needed. 🟢 “Thioctic Acid for Hair Regrowth - Quick Reference Sheet”; no entities required.
6.2 [header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded as needed. 🟢 “Thioctic Acid for Hair Regrowth”.
6.3 [header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY] 🟢 2026-0708-2204 → 07/08/2026.
6.4 [header_subline_model] is set to [qrs_creator_ai_fullname] 🟢 “Opus 4.8”.
6.5 No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker. 🟢 Header carries only the standard subline.

7. At-A-Glance Section

# Description Result Comments
7.1 [at_a_glance] is dense, execution-oriented summary of the ER Conclusion section 🟢 Faithfully condenses the Conclusion.
7.2 [at_a_glance] is no longer than 60 words 🟢 52 words.
7.3 Every fact in [at_a_glance] is supported by a distinct passage in the ER. 🟢 Each clause maps to the Conclusion.
7.4 It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead 🟢 Plain-language throughout (“energy”, “broad antioxidant”).
7.5 It DOES NOT cite specific trials (names, years, sample sizes, p-values) 🟢 No trials cited.
7.6 It DOES NOT cite effect sizes, relative risks, or statistical results 🟢 No statistics present.

8. Contraindications

# Description Result Comments
8.1 The section is derived from the ER Key Interactions & Contraindications section 🟢 Drawn from the ER “Populations who should avoid” bullet.
8.2 [stop_items] represent the Contraindications from the ER 🟢 All six populations mirrored.
8.3 Individual [stop_items] are formatted as <li></li> 🟢 Each item is an <li>.
8.4 Items are as concise as possible. No trailing explanations, elaborations, mechanistic rationale, attributions, citations, study details, or content after a dash. 🟢 Items are bare facts; no trailing clauses.
8.5 Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved, kept as concise as possible. 🟢 “(Child-Pugh Class C)” preserved.
8.6 When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol. N/A The ER contraindications use no ranking notation.
8.7 If no [stop_items] are present the section is left empty N/A Contraindications are present.

9. Key Interactions

# Description Result Comments
9.1 The section is derived from the ER Key Interactions & Contraindications section 🟢 Drawn from the ER interaction bullets.
9.2 [caution_items] represent the Key Interactions from the ER, excluding any that are already listed as Contraindications 🟢 Glucose-lowering drugs, levothyroxine, glucose-lowering supplements, minerals; cancer therapy excluded (listed as a contraindication); antacids excluded (“no major interaction”).
9.3 Individual [caution_items] are formatted as <li></li> 🟢 Each item is an <li>.
9.4 Items are as concise as possible. No trailing explanations, elaborations, mechanistic rationale, attributions, citations, study details, or content after a dash. 🟢 Items are concise.
9.5 Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved, kept as concise as possible. 🟢 Example drug lists preserved and trimmed (e.g., “(insulin, sulfonylureas, meglitinides)”).
9.6 When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol. N/A No ranking notation in the ER interactions.
9.7 If no [caution_items] are present the section is left empty N/A Key Interactions are present.

10. Protocol

# Description Result Comments
10.1 The section is derived from the ER Protocol section 🟢 Dose, timing, and R-isomer drawn from the ER Therapeutic Protocol.
10.2 The three sets of [action] items cover the three most important actionable implementation aspects from the ER Protocol section 🟢 Typical oral dose, best time of day, R-isomer dosing.
10.3 If less that three distinct actionable implementation aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing. N/A The ER provides more than three actionable aspects.
10.4 All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from the ER Protocol section. 🟢 All three cells carry ER-derived content.

11. Time to Effect

# Description Result Comments
11.1 The three sets of [time] items cover the three most important time-to-effect aspects from the ER 🟢 The ER provides two time-to-effect aspects; both are covered (hair change; antioxidant/metabolic).
11.2 The sets are picked and ordered by the magnitude of the related benefit 🟢 Hair change (primary relevant outcome) precedes the non-hair antioxidant/metabolic effect.
11.3 If less that three distinct time-to-effect aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing. 🟢 Third cell (time_3) is empty and display:none.
11.4 All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER. 🟢 Both used cells carry ER-derived content.
11.5 If the ER does not provide any information on time to effect, the section is removed completely from the Protocol Panel N/A The ER does provide time-to-effect information.

12. Benefits

# Description Result Comments
12.1 The section is derived from the ER Expected Benefits section 🟢 Low and Speculative tiers mirror the ER.
12.2 Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative] 🟢 All four spans present.
12.3 Items are as concise as possible. No explanations, elaborations, effect sizes, qualifiers, attributions, citations, study details, or mechanistic explanations. 🟢 Bare benefit statements only.
12.4 Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. 🟢 No parentheticals carried.
12.5 If no items of a specific sub-section are present the respective span is set to “display=none”, not filled with empty-state phrasing. 🟢 benefits_high and benefits_medium set to display:none (ER has no High/Medium benefits).

13. Risks

# Description Result Comments
13.1 The section is derived from the ER Potential Risks & Side Effects section 🟢 Medium, Low, and Speculative tiers mirror the ER.
13.2 Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative] 🟢 All four spans present.
13.3 Items are as concise as possible. No explanations, elaborations, effect sizes, qualifiers, attributions, citations, study details, or mechanistic explanations. 🟢 Bare risk statements only.
13.4 Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. 🟢 “(Hypoglycemia Risk)” and “(Autoimmune Hypoglycemia)” stripped.
13.5 If no items of a specific sub-section are present the respective span is set to “display=none”, not filled with empty-state phrasing. 🟢 risks_high set to display:none (ER has no High risks).

14. Monitoring

# Description Result Comments
14.1 The section is derived from the ER Monitoring section 🟢 Biomarker table and cadence drawn from the ER Monitoring Protocol.
14.2 All measurable/quantifiable biomarkers from the Monitoring section are listed 🟢 Ferritin, TSH, fasting glucose, HbA1c, fasting insulin, vitamin D — all six present with matching targets.
14.3 [monitoring_cadence] is populated with the monitoring cadence/frequency derived from the ER Monitoring section. It is not left with placeholder text or empty. 🟢 Cadence: baseline, recheck ~3 months, then every 6–12 months.

15. Qualitative Assessment

# Description Result Comments
15.1 The section is derived from the ER Monitoring section 🟢 Qualitative markers drawn from the ER Monitoring Protocol.
15.2 All subjective/qualitative biomarkers from the Monitoring section are listed 🟢 Standardized photographs, shedding count, perceived hair quality, energy/well-being — all four present.

Issues 08/07/2026 22:12

Pass rate 100.00%. No issues found.